Human Genome Epidemiology Literature Finder
|
Records 1 - 17 (of 17 Records) |
| Query Trace: Colorectal Neoplasms and ABCC2[original query] |
|---|
| Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biological & pharmaceutical bulletin 2008 Nov 31 (11): 2137-42. Fujita Ken-ichi, Nagashima Fumio, Yamamoto Wataru, Endo Hisashi, Sunakawa Yu, Yamashita Keishi, Ishida Hiroo, Mizuno Keiko, Matsunaga Mototsugu, Araki Kazuhiro, Tanaka Ryuhei, Ichikawa Wataru, Miya Toshimichi, Narabayashi Masaru, Akiyama Yuko, Kawara Kaori, Ando Yuichi, Sasaki Yasutsu |
| Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. Drug metabolism and pharmacokinetics 2011 Dec . Akiyama Y, Fujita KI, Ishida H, Sunakawa Y, Yamashita K, Kawara K, Miwa K, Saji S, Sasaki Y |
| A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. The pharmacogenomics journal 2013 Oct 13 (5): 403-9. Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, Toffoli |
| Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy. Molecular medicine reports 2013 Feb 7 (2): 2. Mirakhorli M, Rahman SA, Abdullah S, Vakili M, Rozafzon R, Khoshzaban A |
| Interactions between meat intake and genetic variation in relation to colorectal cancer. Genes & nutrition 2015 Jan 10 (1): 448. Andersen Vibeke, Vogel Ul |
| Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. Scientific reports 2014 4 6828. Ruzzo Annamaria, Graziano Francesco, Galli Fabio, Giacomini Elisa, Floriani Irene, Galli Francesca, Rulli Eliana, Lonardi Sara, Ronzoni Monica, Massidda Bruno, Zagonel Vittorina, Pella Nicoletta, Mucciarini Claudia, Labianca Roberto, Ionta Maria Teresa, Veltri Enzo, Sozzi Pietro, Barni Sandro, Ricci Vincenzo, Foltran Luisa, Nicolini Mario, Biondi Edoardo, Bramati Annalisa, Turci Daniele, Lazzarelli Silvia, Verusio Claudio, Bergamo Francesca, Sobrero Alberto, Frontini Luciano, Magnani Mau |
| ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenetics and genomics 2015 Sep . Chen Sylvia, Villeneuve Lyne, Jonker Derek, Couture Félix, Laverdière Isabelle, Cecchin Erica, Innocenti Federico, Toffoli Giuseppe, Lévesque Eric, Guillemette Chant |
| AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin. The pharmacogenomics journal 2015 Aug . Kjersem J B, Thomsen M, Guren T, Hamfjord J, Carlsson G, Gustavsson B, Ikdahl T, Indrebø G, Pfeiffer P, Lingjærde O, Tveit K M, Wettergren Y, Kure E |
| Polymorphisms in ATP-binding cassette transporter genes and interaction with diet and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study. Scandinavian journal of gastroenterology 2015 Dec 50 (12): 1469-81. Kopp Tine Iskov, Andersen Vibeke, Tjonneland Anne, Vogel Ul |
| Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer chemotherapy and pharmacology 2015 Apr 75 (4): 763-72. Joerger M, Huitema A D R, Boot H, Cats A, Doodeman V D, Smits P H M, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny T D, Beijnen J H, Schellens J H |
| OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. British journal of cancer 2015 Mar 112 (5): 857-65. Teft W A, Welch S, Lenehan J, Parfitt J, Choi Y-H, Winquist E, Kim R |
| Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. Frontiers in pharmacology 2017 8 712. Labriet Adrien, De Mattia Elena, Cecchin Erika, Lévesque Éric, Jonker Derek, Couture Félix, Buonadonna Angela, D'Andrea Mario, Villeneuve Lyne, Toffoli Giuseppe, Guillemette Chant |
| Effect of UGT, SLCO, ABCB and ABCC polymorphisms on irinotecan toxicity. Medicina clinica 2018 Feb . García Gil Sara, Ramos Díaz Ruth, Nazco Casariego Gloria Julia, Llanos Muñoz Marta, Viña Romero Maria Micaela, Martín Calero Braulio, Pérez Pérez Jose Antonio, Gutiérrez Nicolás Fernan |
| Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy. Asian Pacific journal of cancer prevention : APJCP 2018 Oct 19 (10): 2757-2764. Treenert Apatsara, Areepium Nutthada, Tanasanvimon Suebpo |
| Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? The pharmacogenomics journal 2019 Feb . Nichetti Federico, Falvella Felicia Stefania, Miceli Rosalba, Cheli Stefania, Gaetano Raffaella, Fucà Giovanni, Infante Gabriele, Martinetti Antonia, Antoniotti Carlotta, Falcone Alfredo, Di Bartolomeo Maria, Cremolini Chiara, de Braud Filippo, Pietrantonio Filip |
| Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Scientific reports 2020 Aug 10 (1): 13486. Atasilp Chalirmporn, Chansriwong Phichai, Sirachainan Ekaphop, Reungwetwattana Thanyanan, Sirilerttrakul Suwannee, Chamnanphon Monpat, Puangpetch Apichaya, Sukasem Chonlaph |
| Clinical Impact of X-Ray Repair Cross-Complementary 1 (XRCC1) and the Immune Environment in Colorectal Adenoma-Carcinoma Pathway Progression. Journal of inflammation research 2021 11 14 5403-5417. Zhang Yu, Zhang Xin, Jin Zhuoyi, Chen Huiyan, Zhang Chenjing, Wang Wangyue, Jing Jiyong, Pan Wenshe |
- Page last reviewed:Feb 1, 2023
- Page last updated:Jun 02, 2023
- Content source: